Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Gains from Investment Securities (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Gains from Investment Securities for 7 consecutive years, with -$5.1 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 194.11% to -$5.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.9 million through Dec 2025, up 22.1% year-over-year, with the annual reading at $1.7 million for FY2025, 85.22% down from the prior year.
  • Gains from Investment Securities hit -$5.1 million in Q4 2025 for BridgeBio Pharma, down from $1.3 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $12.2 million in Q2 2025 to a low of -$5.1 million in Q4 2025.
  • Historically, Gains from Investment Securities has averaged $329053.5 across 5 years, with a median of $46148.0 in 2021.
  • Biggest YoY gain for Gains from Investment Securities was 214738.71% in 2025; the steepest drop was 194.11% in 2025.
  • Year by year, Gains from Investment Securities stood at -$2.8 million in 2021, then surged by 46.97% to -$1.5 million in 2022, then tumbled by 134.02% to -$3.5 million in 2023, then surged by 255.22% to $5.5 million in 2024, then plummeted by 194.11% to -$5.1 million in 2025.
  • Business Quant data shows Gains from Investment Securities for BBIO at -$5.1 million in Q4 2025, $1.3 million in Q3 2025, and $12.2 million in Q2 2025.